Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Infertility: HELP
Articles by Christine Rousset-Jablonski
Based on 4 articles published since 2008

Between 2008 and 2019, C. Rousset-Jablonski wrote the following 4 articles about Infertility.
+ Citations + Abstracts
1 Guideline [Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumors: Guidelines from the French national network dedicated to rare gynaecological cancer]. 2018

Rousset-Jablonski, Christine / Selle, Fréderic / Adda-Herzog, Elodie / Planchamp, François / Selleret, Lise / Pomel, Christophe / Chabbert-Buffet, Nathalie / Daraï, Emile / Pautier, Patricia / Trémollières, Florence / Guyon, Frederic / Rouzier, Roman / Laurence, Valérie / Chopin, Nicolas / Faure-Conter, Cécile / Bentivegna, Enrica / Vacher-Lavenu, Marie-Cécile / Lhomme, Catherine / Floquet, Anne / Treilleux, Isabelle / Lecuru, Fabrice / Gouy, Sébastien / Kalbacher, Elsa / Genestie, Catherine / de la Motte Rouge, Thibault / Ferron, Gwenael / Devouassoux-Shisheboran, Mojgan / Kurtz, Jean-Emmanuel / Namer, Moise / Joly, Florence / Pujade-Lauraine, Eric / Grynberg, Michael / Querleu, Denis / Morice, Philippe / Gompel, Anne / Ray-Coquard, Isabelle. ·Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. Electronic address: christine.rousset-jablonski@lyon.unicancer.fr. · Groupe hospitalier Diaconesses Croix-Saint-Simon, 12-18, rue du Sergent-Bauchat, 75012 Paris, France. · Hôpital Foch, service de gynécologie-obstétrique, 40, rue Worth, 92151 Suresnes, France. · Institut Bergonié, 229, Cours-de-l'Argonne, 33000 Bordeaux, France. · Hôpital Tenon, service de gynécologie-obstétrique et médecine de la reproduction, 4, rue de la Chine, 75020 Paris, France. · Centre Jean-Perrin, 58, rue Montalembert BP, 392, 63011 Clermont-Ferrand cedex 1, France. · Institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94800 Villejuif, France. · Hôpital Paule-de-Viguier, centre de ménopause et de dépistage de l'ostéoporose, 330, avenue de Grande-Bretagne, TSA 70034, 31059 Toulouse cedex 9, France. · Institut Curie, 26, rue d'Ulm, 75005 Paris, France. · Centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France. · Hôpital Cochin-Port Royal, 53, avenue de l'Observatoire, 75014 Paris, France. · Hôpital Européen Geroges-Pompidou, 20, rue Leblanc, 75015 Paris, France. · CHU Besançon-Jean-Minjoz, 3, boulevard Alexandre-Fleming, 25030 Besançon cedex, France. · Centre Eugène-Marquis, avenue de la Bataille-Flandres-Dunkerque, 35000 Rennes, France. · CLCC, institut Claudius-Regaud, IUCT Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France. · Hospices civils de Lyon, centre hospitalier Lyon-Sud, 165, chemin du grand-Revoyet, 69495 Pierre-Bénite cedex, France. · CHU de Strasbourg, hôpital de Hautepierre, avenue Molière, 67200 Strasbourg, France. · Recommandations pour la pratique clinique, Nice-Saint-Paul, 06000 Nice, France. · Centre François-Baclesse, 3, avenue du Général-Harris, 14076 Caen cedex 5, France. · CHU Paris Centre, hôpital Hôtel-Dieu, 1, place du Parvis-Notre-Dame, 75004 Paris, France. · Hôpital Jean-Verdier, avenue du 14 juillet, 93140 Bondy, France. ·Bull Cancer · Pubmed #29397916.

ABSTRACT: INTRODUCTION: Rare ovarian tumors include complex borderline ovarian tumors, sex-cord tumors, germ cell tumors, and rare epithelial tumors. Indications and modalities of fertility preservation, infertility management and contraindications for hormonal contraception or menopause hormone therapy are frequent issues in clinical practice. A panel of experts from the French national network dedicated to rare gynaecological cancers, and of experts in reproductive medicine and gynaecology have worked on guidelines about fertility preservation, contraception and menopause hormone therapy in women treated for ovarian rare tumors. METHODS: A panel of 39 experts from different specialties contributed to the preparation of the guidelines, following the DELPHI method (formal consensus method). Statements were drafted after a systematic literature review, and then rated through two successive rounds. RESULTS: Thirty-five recommendations were selected, and concerned indications for fertility preservation, contraindications for ovarian stimulation (in the context of fertility preservation or for infertility management), contraceptive options (especially hormonal ones), and menopause hormone therapy for each tumor type. Overall, prudence has been recommended in the case of potentially hormone-sensitive tumors such as sex cord tumors, serous and endometrioid low-grade adenocarcinomas, as well as for high-risk serous borderline ovarian tumors. DISCUSSION: In the context of a scarce literature, a formal consensus method allowed the elaboration of guidelines, which will help clinicians in the management of these patients.

2 Review [Gonadal function after treatment for a childhood or adolescent cancer]. 2015

Rousset-Jablonski, Christine / Giscard d'Estaing, Sandrine / Bernier, Valérie / Lornage, Jacqueline / Thomas-Teinturier, Cécile / Aubier, Françoise / Faure-Conter, Cécile. ·Centre Léon-Bérard, département de chirurgie, 69008 Lyon, France. · Centre d'étude et de conservation des œufs et du sperme humain (CECOS), hôpital femme-mère-enfant, 69500 Bron, France. · Institut de cancérologie de Lorraine, département de radiothérapie, 54500 Vandœuvre-lès-Nancy, France. · Hôpital Femme-Mère-Enfant, service de médecine de la reproduction, 69500 Bron, France. · AP-HP, site de Bicêtre, service d'endocrinologie et de diabétologie pédiatrique, 94270 Le Kremlin-Bicêtre, France. · Hôpital d'enfants, 95580 Margency, France. · Institut d'hématologie et d'oncologie pédiatrique (IHOP), département d'oncologie pédiatrique, 69008 Lyon, France. Electronic address: cecile.conter@lyon.unicancer.fr. ·Bull Cancer · Pubmed #25890827.

ABSTRACT: Due to high cure rate in childhood and adolescent cancer, fertility preservation is a major concern. Chemotherapy, radiotherapy and surgery may alter gonadal function, and uterine cavity in women. In women, combined toxicity affecting both endocrine function and ovulation are observed leading to premature ovarian insufficiency. In men, spermatogenesis is frequently affected whereas endocrine function is almost always preserved. The current article focuses on investigations concerning gonadal function after treatment for a cancer during childhood or adolescence and treatment of subsequent infertility or hypogonadism. Nevertheless, those therapeutic are still limited and pretherapeutic preservation of fertility is preferred when possible.

3 Article [Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation?]. 2015

Sénéchal, C / Rousset-Jablonski, C. ·Gynécologue médicale, unité d'oncogénétique, institut Bergonié, 229, cours de l'Argonne, 33000 Bordeaux, France. · Gynécologue médicale, département de chirurgie, centre Léon-Bérard, 28, rue Laënnec, 69008 Lyon, France; Service de gynécologie obstétrique, centre hospitalier Lyon Sud, hospices civils de Lyon, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France. Electronic address: christine.rousset-jablonski@lyon.unicancer.fr. ·Gynecol Obstet Fertil · Pubmed #26476890.

ABSTRACT: Should all women with BRCA1 or BRCA2 genes mutations be considered at risk of prematurely impaired fertility, and thus should a fertility preservation systematically be proposed? Women carrying mutations of BRCA1 or BRCA2 are at high risk for breast and tubo-ovarian cancer. The treatment of a breast cancer at a young age, unrare in this population, is associated with a risk of infertility, due to the ovarian toxicity of chemotherapy, to the recommended duration of hormonotherapy when indicated, and to the time advised before starting a pregnancy. Furthermore, some data in the literature suggest a higher risk of premature ovarian failure among women with BRCA1/2 mutation: advance of the age at menopause and poorer response to ovarian stimulation have been observed. Several pathophysiological hypotheses support this finding, as the involvement of the BRCA genes in maintaining telomere length, the DNA repair anomalies promoting oocyte apoptosis, differences in FMR1 genotype. Current fertility preservation techniques have limitations, some of them being specific to BRCA1/2 women: absence of oncological risk due to stimulation in BRCA1/2 women not clearly demonstrated, oocyte vitrification techniques limited rentability, graft of ovarian cortex not suitable in these women at high risk. Thus, data on the increased risk of premature ovarian failure remaining weak, such a systematic proposal seems questionable.

4 Article Catamenial pneumothorax and endometriosis-related pneumothorax: clinical features and risk factors. 2011

Rousset-Jablonski, Christine / Alifano, Marco / Plu-Bureau, Geneviève / Camilleri-Broet, Sophie / Rousset, Pascal / Regnard, Jean-François / Gompel, Anne. ·Department of Gynecological Endocrinology, Université Paris Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Hôtel Dieu, 75181 Paris Cedex 4, France. anne.gompel@htd.aphp.fr ·Hum Reprod · Pubmed #21685141.

ABSTRACT: BACKGROUND: Catamenial pneumothorax and thoracic endometriosis (TE) are still under diagnosed. The purpose of this study is to increase the diagnostic accuracy for these conditions in patients with spontaneous pneumothorax and to identify their risk factors. METHODS: We conducted a retrospective study on all consecutive women of reproductive age referred to our Centre for surgical treatment of spontaneous pneumothorax between July 2000 and January 2009. RESULTS: The study population comprised 156 premenopausal women of whom 49 (31.4%) had catamenial and/or TE-related pneumothorax. Over a quarter of these 49 patients had a previous history of recurrent thoracic or scapular catamenial pain. They experienced their first pneumothorax episode at an older age (mean ± SD) (34.0 years ± 6.7) than women with idiopathic pneumothorax (28.7 ± 6.1 years, P < 0.001). Pelvic endometriosis was found in 51% of women with catamenial and/or TE-related pneumothorax. After adjustment for confounding factors by multiple logistic regression analysis, the results show that, infertility [odd ratio (OR) = 4.21, 95% confidence interval (CI) = 1.28-13.88] and a history of pelvic surgery with a uterine procedure and/or uterine scraping (OR = 2.85, 95% CI = 1.12-7.26) were the strongest predictors of catamenial and/or TE-related pneumothorax. CONCLUSIONS: Infertility and uterine procedures are significantly associated with catamenial and/or TE-related pneumothorax. Scapular or thoracic pain during menses often precedes the occurrence of pneumothorax and is highly specific for the diagnosis of TE. Our results suggest that in women with pelvic endometriosis, these symptoms should be systematically investigated for an earlier diagnosis of TE.